Grants for Native American tribal organizations - Food and Nutrition

The purpose of this funding opportunity is to support the research and development necessary to advance non-invasive (e.g., quantitative tomography-based) technologies, including the development of apparatus, methods, study designs, and methods of data analysis, to characterize and compare the rate and extent to which a topically applied drug becomes available at or near a site of action within the skin in vivo. The expectation is that the funded work will produce an accurate, sensitive and reproducible approach that rapidly measures the (relative) amount of drug present in the skin at a series of depths below the skin surface, which can be utilized to monitor the cutaneous pharmacokinetics (PK) of the drug at selected depths (e.g., in the epidermis) by repeated, serial measurements over time. The intent is to support the eventual development of an alternative, scientifically valid, in vivo cutaneous PK-based approach that can be used to efficiently demonstrate the bioequivalence (BE) of topical products.

The objective of this research proposal is to develop physiologically based pharmacokinetic (PBPK) model-based mechanistic in vitro in vivo correlations (IVIVCs) for two major types of long acting injectables (LAIs) such as crystalline suspensions and polymer-based implants by considering their distinct characteristics. The goal of the project is to develop a bottom-up mechanistic PBPK model for these two LAI categories by accounting for the influence of critical formulation attributes of each LAI drug product type to predict its in vivo release mechanism. The model formulation parameters and relevant physiology should be informed with suitable in vitro and in vivo experiments. A suitable preclinical animal model can be used to validate the PBPK model based IVIVCs for both LAI suspensions and polymer based implants. The use of PBPK modelling provides a unique opportunity to understand how the physicochemical properties of drug molecules/polymer, implant specific properties, critical formulation attributes, and physiology, among other things, influence the in vivo release mechanisms of LAI drug products and their disposition characteristics. Moreover, once developed, a mechanistic PBPK model can help to define the 'safe space' for critical formulation attributes relevant to the reference listed drug (RLD) product, explain sources of PK variability and extrapolate predictions to human subjects by leveraging animal model data and by accounting for species-specific physiological differences.

The GOODS Program is a grant opportunity provided by Greater Good Charities. It aims to distribute food, essential supplies, clothing, housewares, toys, and more to pets and people in need across the world. The program helps various constituents including pets (homeless and owned), families facing economic hardships, unhoused populations, military veterans, domestic violence survivors, victims of disasters, and displaced persons. The GOODS Program works by sourcing and managing excess, re-branded, and short-dated food and supplies from donors such as manufacturers, distributors, and retailers. These products are then made available to qualified distribution groups called Ambassadors who ensure they reach the organizations in need known as Recipients. The program operates through a sustainable hub and spoke model similar to a food bank where goods are donated but costs are covered by handling fees and donations. To apply as a Recipient organization, interested parties can locate the nearest Ambassador on the program's website and apply directly through their website. For general inquiries or to inquire about grants and services, individuals can contact Greater Good Charities through their website or send checks to their designated address in Seattle, WA.

Computational fluid dynamics (CFD) has played a crucial role in providing an alternative bioequivalence (BE) approach for generic orally inhaled drug products (OIDPs), in addition to comparative clinical endpoint or pharmacodynamic BE studies, as a relatively cost- and time-efficient complement to benchtop and clinical experiments that has been widely used in developing and assessing generic inhaler devices. However, despite the advances in the power of modern computers, there are still some bottlenecks in using CFD due to computational time, limited grid resolution, pre- and post-processing of large simulation data sets, model parameter estimations, and uncertainty quantifications. Machine learning (ML) has been gaining more attention as a potential tool to alleviate such limitations that arise in CFD. The purpose of this grant is to develop a methodology to integrate ML with CFD models of OIDPs to promote alternative BE studies to enhance and accelerate the development and approval of generic OIDPs.

This funding opportunity supports U.S.-based researchers and organizations in developing non-addictive pain relief therapies to combat the opioid crisis, with a focus on advancing preclinical candidates toward clinical trials.

The Silvio O. Conte Digestive Diseases Research Core Centers grant, provided by the NIDDK, supports collaborative research on digestive and liver diseases by offering shared resources to enhance productivity and foster new ideas, centered around a theme within the NIDDK's mission.

This funding opportunity provides financial support for new and underrepresented researchers in the health sciences to conduct projects aligned with the missions of NIAID or NIDDK.

This funding opportunity supports postdoctoral researchers in biomedical and behavioral fields, providing mentorship and resources to help them develop into independent scientists.

This funding opportunity supports predoctoral students in dual-degree programs at institutions without NIH-funded training programs, helping them pursue research and clinical training to become future physician-scientists.

This funding opportunity supports students enrolled in dual-degree medical and research training programs, helping them develop into independent physician-scientists through mentored research and clinical training.

This funding opportunity supports institutions in creating collaborative training networks for early-career researchers focused on advancing studies in kidney, urologic, and hematologic diseases.

This program provides affordable funding to develop essential community facilities in rural areas. An essential community facility is defined as a facility that provides an essential service to the local community for the orderly development of the community in a primarily rural area, and does not include private, commercial or business undertakings. Funds can be used to purchase, construct, and / or improve essential community facilities, purchase equipment and pay related project expenses. Examples of essential community facilities include: -Health care facilities such as hospitals, medical clinics, dental clinics, nursing homes or assisted living facilities -Public facilities such as town halls, courthouses, airport hangars or street improvements -Community support services such as child care centers, community centers, fairgrounds or transitional housing -Public safety services such as fire departments, police stations, prisons, police vehicles, fire trucks, public works vehicles or equipment -Educational services such as museums, libraries or private schools -Utility services such as telemedicine or distance learning equipment -Local food systems such as community gardens, food pantries, community kitchens, food banks, food hubs or greenhouses What are the funding priorities? ---Priority point system based on population, median household income -Small communities with a population of 5,500 or less -Low-income communities having a median household income below 80% of the state nonmetropolitan median household income.

This funding opportunity provides financial support to various organizations, including universities and non-profits, to improve veterinary diagnostic capabilities and address public health issues related to animal food safety and antimicrobial resistance.

This funding opportunity supports research projects aimed at reducing stigma related to HIV/AIDS in low- and middle-income countries, with a focus on improving health outcomes for affected populations.

This funding opportunity supports research initiatives focused on non-communicable diseases related to HIV at institutions in low- and middle-income countries, encouraging innovative projects and collaborations to improve health outcomes for people living with HIV.

This funding opportunity supports interdisciplinary research teams to explore how medical devices can effectively relieve chronic pain while minimizing addiction risks.

This funding opportunity supports the development of innovative tools and technologies aimed at advancing research and treatment in kidney, urologic, and hematologic diseases, encouraging projects that push scientific boundaries and have broad applications beyond individual research interests.

This funding opportunity provides substantial financial support to higher education institutions and nonprofit organizations to establish collaborative centers that advance research and resources for HIV/AIDS.

This funding opportunity provides significant financial support to U.S. higher education institutions and research organizations with established HIV/AIDS research programs, enabling them to enhance their research infrastructure and foster interdisciplinary collaboration in the fight against HIV/AIDS.

This funding opportunity provides financial support for small clinical trials focused on preventing and treating diseases related to diabetes, digestive, kidney, and urologic health, particularly targeting underserved populations to improve health outcomes.